State Street Corp Raises Stock Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

State Street Corp grew its position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 19.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,793,728 shares of the company's stock after acquiring an additional 297,511 shares during the quarter. State Street Corp owned about 3.74% of Mirum Pharmaceuticals worth $69,955,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Mirum Pharmaceuticals by 22.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,725 shares of the company's stock valued at $67,000 after acquiring an additional 318 shares during the period. Amalgamated Bank boosted its stake in shares of Mirum Pharmaceuticals by 60.8% during the second quarter. Amalgamated Bank now owns 1,357 shares of the company's stock valued at $46,000 after purchasing an additional 513 shares during the period. Arizona State Retirement System grew its holdings in shares of Mirum Pharmaceuticals by 10.6% in the second quarter. Arizona State Retirement System now owns 9,210 shares of the company's stock worth $315,000 after purchasing an additional 883 shares during the last quarter. Quest Partners LLC increased its stake in Mirum Pharmaceuticals by 7,513.3% in the 2nd quarter. Quest Partners LLC now owns 1,142 shares of the company's stock worth $39,000 after buying an additional 1,127 shares during the period. Finally, Commonwealth Equity Services LLC lifted its holdings in Mirum Pharmaceuticals by 17.1% during the 2nd quarter. Commonwealth Equity Services LLC now owns 14,050 shares of the company's stock valued at $480,000 after buying an additional 2,050 shares in the last quarter.

Wall Street Analyst Weigh In

A number of equities analysts have commented on MIRM shares. Robert W. Baird upped their target price on shares of Mirum Pharmaceuticals from $44.00 to $50.00 and gave the stock an "outperform" rating in a research note on Wednesday, November 13th. Citigroup increased their price objective on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a "buy" rating in a research note on Wednesday, November 13th. HC Wainwright restated a "buy" rating and set a $66.00 price objective on shares of Mirum Pharmaceuticals in a report on Wednesday, November 13th. Finally, Leerink Partners upped their target price on Mirum Pharmaceuticals from $47.00 to $49.00 and gave the stock an "outperform" rating in a report on Thursday, October 17th. Ten investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $57.73.

Insider Transactions at Mirum Pharmaceuticals

In other news, SVP Jolanda Howe sold 2,500 shares of the business's stock in a transaction dated Thursday, November 14th. The stock was sold at an average price of $47.10, for a total transaction of $117,750.00. Following the sale, the senior vice president now owns 2,426 shares in the company, valued at approximately $114,264.60. The trade was a 50.75 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 22.87% of the company's stock.

Mirum Pharmaceuticals Price Performance

MIRM opened at $42.65 on Wednesday. The firm has a market capitalization of $2.05 billion, a PE ratio of -21.11 and a beta of 1.20. The company has a debt-to-equity ratio of 1.33, a current ratio of 3.34 and a quick ratio of 3.15. The business's 50-day moving average is $42.04 and its two-hundred day moving average is $39.10. Mirum Pharmaceuticals, Inc. has a 1 year low of $23.14 and a 1 year high of $48.89.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.45) by $0.15. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The firm had revenue of $90.38 million for the quarter, compared to the consensus estimate of $81.99 million. During the same quarter in the previous year, the firm earned ($0.57) EPS. The company's quarterly revenue was up 89.4% compared to the same quarter last year. Research analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.48 earnings per share for the current fiscal year.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.